| dc.contributor.author |
Doležalová, Barbora
|
cze |
| dc.date.accessioned |
2017-05-11T11:24:09Z |
|
| dc.date.available |
2017-05-11T11:24:09Z |
|
| dc.date.issued |
2016 |
cze |
| dc.identifier.issn |
1801-1209 |
cze |
| dc.identifier.uri |
http://hdl.handle.net/10195/67766 |
|
| dc.description.abstract |
Komentovaná post hoc analýza Zinmana a spol. se zaměřuje na účinnost a bezpečnost linagliptinu v kombinaci s léčbou inzulinem. Zahrnuje pacienty ze čtyř randomizovaných studií III. fáze, kteří se inzulinem léčili již před vstupem do těchto studií. |
cze |
| dc.format |
p. 57-59 |
cze |
| dc.language.iso |
cze |
cze |
| dc.relation.ispartof |
Farmakoterapie, volume 12, issue: 1 |
cze |
| dc.rights |
Pouze v rámci univerzity |
cze |
| dc.subject |
Linagliptin |
cze |
| dc.subject |
diabetes mellitus 2. typu |
cze |
| dc.subject |
post-hoc analýza |
cze |
| dc.subject |
Lingliptin |
eng |
| dc.subject |
type 2 diabetes mellitus |
eng |
| dc.subject |
post-hoc analysis |
eng |
| dc.title |
Komentář ke studii: Účinnost a kardiovaskulární bezpečnost linagliptinu po přidání k inzulinu u diabetu 2. typu |
cze |
| dc.title.alternative |
Comment on a study: Efficacy and cardiovascular safety of linagliptin as an add-on to insulin in type 2 diabetes |
eng |
| dc.type |
article |
cze |
| dc.description.abstract-translated |
The commented post-hoc analysis made by Zinman et al. focuses on linagliptin in combination with insulin in type 2 diabetes treatment. It comprises patients from four randomised Phase III studies who were treated with insulin before being randomised in these studies. |
eng |
| dc.peerreviewed |
yes |
cze |
| dc.publicationstatus |
pulished version |
cze |
| dc.identifier.obd |
39878592 |
cze |
